- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biologic agents in juvenile spondyloarthropathies ; volume:14 ; number:1 ; day:12 ; month:3 ; year:2016 ; pages:1-8 ; date:12.2016
Pediatric rheumatology ; 14, Heft 1 (12.3.2016), 1-8, 12.2016
- Urheber
-
Katsicas, María Martha
- Beteiligte Personen und Organisationen
-
Russo, Ricardo
SpringerLink (Online service)
- DOI
-
10.1186/s12969-016-0076-6
- URN
-
urn:nbn:de:1111-2016031538460
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Katsicas, María Martha
- Russo, Ricardo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
Influence of combined chemotherapeutic agents on cell biologic response of B-cell lymphomas
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
Influence of combined chemotherapeutic agents on cell biologic response of B-cell lymphomas
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
Influence of combined chemotherapeutic agents on cell biologic response of B-cell lymphomas